The present invention is directed to substituted indanyl compounds of
Formula (I): ##STR00001## Useful for treating integrin-mediated
disorders such as, but not limited to unstable angina, thromboemboic
disorders, osteoporosis, growth and metastasis of malignant tumors,
diabetic retinopathy, arthritis, viral disease and surgical adhesions.